Breast cancer is often treated with tamoxifen, a drug that can cause ocular side effects, including toxic retinopathy. Multimodal imaging, particularly optical coherence tomography (OCT), has improved the detection of early lesions such as foveal pseudocysts, thus increasing the prevalence of this complication. We present a case of tamoxifen-induced retinopathy in a patient treated for four years who developed decreased visual acuity with irreversible retinal lesions in the right eye despite discontinuation of the treatment. OCT was essential in characterizing the lesions. The pathophysiology remains poorly understood, but involvement of Müller cells and glutamate accumulation in the retinal pigment epithelium are suspected. Toxicity depends on cumulative dose, duration of treatment, and individual factors. Initial ophthalmologic screening and regular OCT monitoring are recommended to detect retinal damage early. In case of lesions, substitution with an aromatase inhibitor is often considered to limit lesion progression and preserve vision.

Sex and gender influence cancer risk, prognosis, and response to treatment. Sex modulates the incidence, efficacy, and toxicity of systemic therapies. Overall, most cancers are more frequent in men, except for thyroid cancer, which is more common in women. Women have better survival rates than men for several tumor sites, but they experience more toxicity from anticancer treatments. For targeted therapies, the unequal distribution of molecular alterations between sexes mainly affects the drug indications rather than their intrinsic efficacy. In immunotherapy, women seem to achieve a smaller relative benefit, possibly due to a more active immune system at baseline. These differences require general practitioners to adapt oncological follow-up, ensure early detection of toxicities, and provide sex-specific preventive counselling.

Cardiotoxicity from anti-leukemic therapies remains a major concern in pediatric hemato-oncology - often subclinical in the short term but potentially life-threatening in the long term. In children, who are exposed to cardiotoxic treatments at an early age and have long life expectancies, a proactive strategy for prevention, early detection, and management is essential. Anthracyclines remain a cornerstone of pediatric acute leukemia treatment but are associated with a risk of heart failure in approximately 10% of cases, particularly at cumulative doses exceeding 300mg/m2 of doxorubicin-equivalent. Dexrazoxane, once controversial, is now supported by robust data demonstrating both safety and cardioprotective efficacy. Its use is recommended alongside anthracyclines in patients receiving a cumulative dose≥300mg/m2 of doxorubicin-equivalent. Other agents - including tyrosine kinase inhibitors, immunotherapies, and CAR-T cells - also carry cardiotoxic potential, warranting tailored monitoring strategies. These multidisciplinary SFCE-endorsed recommendations emphasize the need for early and repeated assessment of cardiovascular risk factors throughout treatment. A dedicated heart team, involving pediatric cardiologists and pediatric hematologists, should coordinate active surveillance, including management of modifiable cardiovascular risk factors and systematic imaging with global longitudinal strain, which is more sensitive than ejection fraction in detecting subclinical dysfunction. Prospective pediatric studies are needed to define age-appropriate imaging thresholds, validate the role of cardiac biomarkers, and assess liposomal anthracycline formulations. If confirmed to be both safe and effective, such agents should be integrated into future treatment protocols to enhance long-term cardioprotection without compromising anti-leukemic efficacy.

Chemotherapy-induced peripheral neuropathy (CIPN) is common and disabling. CIPN's sensory and motor symptoms can negatively affect physical function, independence, and quality of life. Physical activity (PA) may help mitigate these adverse effects. In a preventive context, programs combining endurance, resistance, and sensorimotor exercises may reduce the incidence of CIPN, limit certain functional impairments, and improve treatment tolerance. In patients already experiencing CIPN, PA may alleviate symptoms and enhance quality of life. Supervised programs lasting 8 to 12 weeks, with three to five 30 - to 60-minute sessions at a moderate intensity per week are recommended.

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but immune-related adverse events are common. Reactive arthritis-like syndromes remain rarely reported in this context.

Cardio-oncology is a multidisciplinary medical specialty focusing on the prevention, the early detection, and the management of cardiovascular (CV) complications associated with antineoplastic therapies. Currently, CV disease and cancer are the two leading causes of death in the population. These two patient groups overlap when oncology patients experience CV complications related to antineoplastic treatment, or when patients with known CV comorbidities require cancer treatment. Cardio-oncology aims to provide the most effective antitumor therapy while optimizing short- and long-term CV risk for cancer patients.

Therapeutic advances have led to an increase in the number of patients living with cancer, requiring heightened vigilance for cardiovascular complications. This article discusses the monitoring and management of cardiovascular adverse events in cancer patients, particularly those receiving lorlatinib, a third-generation tyrosine kinase inhibitor used in the treatment of advanced non-small cell lung cancer with ALK gene rearrangement. Antitumor treatments such as lorlatinib can cause cardiac and metabolic complications, which has led to the development of cardio-oncology as a specialized discipline. The 5-year data from the CROWN phase III study confirms the efficacy of lorlatinib, but also show the occurrence of significant adverse events, including dyslipidemia (hypercholesterolemia/hypertriglyceridemia), weight gain and hypertension. A multidisciplinary group of experts has therefore drawn up practical proposals for the management of metabolic and cardiovascular side effects associated with lorlatinib. The article addresses the management of dyslipidemia, hypertension, conduction disorders and QT interval prolongation induced by lorlatinib. Finally, nutritional management is discussed, as is the role of adapted physical activity. In conclusion, this article highlights the importance of proactive monitoring and management of adverse cardiovascular events in patients treated with lorlatinib.

Targeted therapies (TT) represent a major breakthrough in oncology, with nearly one hundred agents now available, half of which are administered orally. While their efficacy is unquestionable, their safety profile, particularly cardiovascular (CV), requires close attention. Indeed, the frequency and presentation of these CV toxicities vary according to the TT: arterial hypertension with VEGFR inhibitors, thromboembolic events with abemaciclib, left ventricular dysfunction with osimertinib or BRAF/MEK inhibitors, QTc prolongation with ribociclib or vandetanib, and metabolic disorders (dyslipidemia, hyperglycemia) with PI3K/AKT/mTOR pathway inhibitors. Although severe events remain relatively uncommon, they may impact the continuation of a treatment crucial for cancer prognosis. Data from clinical trials, complemented by pharmacovigilance and real-world studies, now provide a clearer picture of these complications. Prevention and management rely on recent European Society of Cardiology recommendations including initial CV risk assessment (HFA-ICOS score), close clinical and paraclinical monitoring, and tailored management of toxicities. In this setting, cardio-oncology is emerging as an essential discipline, aiming to reconcile anticancer efficacy with cardiovascular safety. A multidisciplinary approach involving oncologists, cardiologists, primary care physicians, and patients is key. Patient education, optimization of risk factors, and individualized monitoring are the cornerstones of optimal care.

The objective was to establish an inventory of the use of complementary therapies, and more particularly acupuncture, in the management of adverse effects of anticancer treatments (ACTs) reported by patients actively treated for solid cancer, as well as to evaluate access to this practice and the experience reported by patients.

The management of locally advanced head and neck tumors is complex due to the multimodal nature of the treatment and the frequent presence of comorbidities in this patient population. International guidelines recommend the use of cisplatin concomitantly with radiotherapy; however, its administration is often limited by contraindications and potential toxicities. The management of treatment-related adverse effects, as well as the use of induction chemotherapy, remains heterogeneous. Therefore, we aimed to assess the current practices of French oncologists in order to identify potential needs and evaluate the relevance of issuing national recommendations to harmonize clinical practice.

Cancer prognosis has steadily improved over recent decades. In 2025, approximately 85% of patients with cancer were in remission. The growing complexity of oncologic treatments has led to substantial gains in progression-free survival, albeit at the cost of increased cardiotoxic risk. Cardiotoxicity most commonly manifests as heart failure or left ventricular dysfunction. Consequently, the cardiovascular mortality of individuals treated for childhood cancers, as well as of older women treated for breast cancer, now equals or even exceeds oncologic mortality.In response, the European Society of Cardiology has issued its first cardio-oncology guidelines, establishing precise thresholds for left ventricular ejection fraction, longitudinal function (as assessed by echocardiographic strain parameters), and selected cardiac biomarkers. Within this framework, it is crucial to develop robust strategies to predict, enable early detection of, and ideally prevent treatment-related adverse cardiac effects. Rigorous control of traditional cardiovascular risk factors remains the cornerstone of preventing oncology-treatment-induced cardiotoxicity.

Anti-PD1 and anti-PD-L1 inhibitors have become central to systemic therapy for solid tumors, reshaping indications and outcomes across multiple tumor types. Their widespread use, however, raises major economic, environmental, and societal challenges. Current regimens - fixed dose, defined frequency, and predetermined duration - are supported by limited clinical and paraclinical evidence. Consistent signals from pharmacokinetic and pharmacodynamic studies, retrospective cohorts and small prospective trials suggest that overtreatment is possible in a significant proportion of patients. In this context, therapeutic de-escalation should be evaluated along three axes: dose reduction, extension of dosing intervals, and adjustment of the total duration of treatment. This review summarizes the current state of knowledge on the pharmacokinetics and pharmacodynamics of checkpoint inhibitors, as well as retrospective and prospective clinical data exploring dose, frequency, and duration de-escalation across different tumor types. It also presents the main trials currently underway to evaluate these strategies and their clinical, economic, and societal impacts.

The therapeutic management of metastatic breast cancers has benefited in the past few years from important progress linked to the development of new molecules, inhibiting poly adenosine diphosphate ribose polymerase (PARP), cyclin-dependent kinases (CDK4/6) or immune checkpoints. More recently, the development of antibody-drug conjugates (ADC) targeting tumor cells, allows for the delivery of cytotoxic agents, at low doses, while increasing their concentration in the tumoral microenvironment. Currently, two ADC are available for the management of HER2-negative metastatic breast cancers, sacituzumab govitecan and trastuzumab deruxtecan. However, these ADC still induce significant grade 3/4 adverse events in more than 40% of the cases. Here, a practical review of the characteristics of these 2 ADC is proposed, with their mode of action and formulation, posology and place in the treatment schedules of HER2-negative metastatic breast cancers. The major results of phase III clinical trials are summarized, and a special focus is made on the management of toxicities.

To describe cases of intraocular inflammation (IOI) observed after intravitreal injections (IVI) of second-generation anti-VEGF agents in a university hospital over 12months in 2024.

Posterior Reversible Encephalopathy Syndrome (PRES) is one of the most common neurological complications in pediatric onco-hematology. Hematologic malignancies and cytotoxic chemotherapy are involved in its pathogenesis. It's a clinical and radiological entity: the diagnosis of PRES is based on both clinical symptoms and neuroimaging data.

The evolution of serous high grade ovarian cancer management is characterized by a more regulated patients' journey on the one hand and the development of new therapeutic options on the other hand, the selection of which is guided by tumor molecular characteristics. Surgery remains the cornerstone of treatment. It can be performed only in authorized expert sites that can demonstrate sufficient experience from highly skilled surgical teams, and quality criteria including prehabilitation and rehabilitation programs. The diagnostic step is crucial; it comprises multiple biopsies that allow reliable pathological and molecular analyses, and a comprehensive surgical staging. Determination of BRCA1/2 mutation and homologous recombination deficiency statuses by validated methods guide maintenance therapy at advanced stages and referring to oncogenetic consultation if appropriate. For these advanced diseases, the two main questions for surgical strategy are the feasibility of complete resection (without residual disease, CC-0), assessed during surgical exploration of pelvis and abdomen, and the optimal timing of this surgery (upfront or after neoadjuvant chemotherapy). In recurrent diseases, surgery remains a main piece of treatment in case of late relapse and medical treatment depends on drugs used in the first line; in early platinum resistant relapse, a new therapeutic option is available with mirvétuximab soravtansine.

New therapeutic options for gynecological cancers (in particular, targeted therapies and immunotherapies) are associated with potential cardiovascular toxicities that oncologists should be able to identify, detect and manage together with a cardiologist. The first step consists of evaluating the patient's individual cardiovascular risk, regardless of planned oncologic treatment, to determine whether this treatment can be initiated immediately or if cardiological advice is required. In a second step, the risk of cardiovascular toxicity of the selected treatment must be assessed, considering its intrinsic risk and the patient's comorbidities. Once treatment has started, appropriate monitoring should be implemented during administration, and after discontinuation. Beyond general recommendations, specific situations are detailed for initial workup and surveillance relating to most common protocols of chemotherapy, immunotherapy, targeted therapy and associations used in gynecological oncology. If cardiotoxicity occurs (hypertension, QT interval increase, left ventricular dysfunction, troponin increase, myocarditis), the oncologist must be aware of the principles of management, and distinguish between what he can manage on his own and what requires referring to specialists. Prior to rechallenge after cardiotoxicity, multidisciplinary discussion is mandatory to assess the patient's benefit/risk ratio.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and significantly improved survival in many tumour types. However, blocking the immune system's inhibitory signaling pathways can trigger an excessive immune response against the body's own tissues, leading to immune-related adverse events (irAEs). These can potentially affect any organ system and represent a significant clinical challenge. This article provides a practical overview of irAEs management, with a particular focus on neurological complications. It presents evidence-based strategies for prevention, diagnosis and treatment, and discusses decision criteria for resuming ICI treatment after an irAE.

The goal of this study was to investigate the efficacy and safety of therapeutic switch of intravitreal injections (IVT) from ranibizumab 10mg/mL (Lucentis®) and aflibercept 40mg/mL (Eylea®) to FYB201 (Ranivisio®) in exudative age-related macular degeneration (AMD). This study includes an analysis of the direct medical cost of managing exudative AMD. The data studied included the mean injection interval in the year preceding the switch and the 9 months following, the longest dry interval over this period, the change in central retinal thickness, tolerance data, the sum of visit costs, treatment costs and an estimate of transportation costs.

The growing number of cancer cases induces increasing pressure on oncology and hematology departments, creating the need for alternatives such as hospitalization at home (HAH). The Carfil-HAD pilot study aimed to assess the feasibility and safety of administering short-duration intravenous carfilzomib infusions at home for the treatment of multiple myeloma. Among the 17 patients included, 15 received 128 infusions of Carfilzomib under a combined Outpatient Hospital (OH)/HAH scheme, are evaluable. Deviations from standard operating procedures were monitored, quality of life and satisfaction were evaluated, and a cost-effectiveness analysis compared the mixed OH/HAH model to exclusive OH care. The results confirmed feasibility: of 128 infusions, 42 were performed in OH and 86 in HAH without serious incident or interruption of care, with 96% of deviations classified as minor. Quality of life is not affected by the mixed care organization, and patient satisfaction was very high. From an economic perspective, the OH/HAH model generated savings of €610 per treatment cycle, nearly half the cost of hospital-based care. In conclusion, intravenous administration of carfilzomib in HAH is feasible and safe. This organization could be applied to other oncological therapies to offer a wider range of outpatient's care.